No Data
Pyxis Oncology Rises on FDA Fast Track Tag for Lead Asset
Express News | Pyxis Oncology Granted FDA Fast Track Designation for Pyx-201 Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
Pyxis Oncology Initiates New PYX-201 Trial, Initiates Cohort Expansions
Express News | Pyxis Oncology Initiates New Pyx-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $8
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Trailside22 : shes a beauty AH.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")